"Receptor, IGF Type 1" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A protein-tyrosine kinase receptor that is closely related in structure to the INSULIN RECEPTOR. Although commonly referred to as the IGF-I receptor, it binds both IGF-I and IGF-II with high affinity. It is comprised of a tetramer of two alpha and two beta subunits which are derived from cleavage of a single precursor protein. The beta subunit contains an intrinsic tyrosine kinase domain.
| Descriptor ID |
D017526
|
| MeSH Number(s) |
D08.811.913.696.620.682.725.400.185 D12.776.543.750.630.468 D12.776.543.750.750.400.780.400
|
| Concept/Terms |
Receptor, IGF Type 1- Receptor, IGF Type 1
- Receptors, IGF-1
- IGF-1 Receptors
- Receptors, IGF 1
- IGF-1 Receptor
- IGF 1 Receptor
- Receptor, IGF-1
- Receptors, Insulin-Like-Growth Factor I
- IGF-I Receptor
- IGF I Receptor
- Receptor, Insulin-Like Growth Factor Type 1
- Receptor, IGF-I
- Receptor, IGF I
- Receptor, Insulin-Like Growth Factor I
- Insulin-Like-Growth Factor I Receptor
- Insulin Like Growth Factor I Receptor
- IGF Type 1 Receptor
|
Below are MeSH descriptors whose meaning is more general than "Receptor, IGF Type 1".
Below are MeSH descriptors whose meaning is more specific than "Receptor, IGF Type 1".
This graph shows the total number of publications written about "Receptor, IGF Type 1" by people in this website by year, and whether "Receptor, IGF Type 1" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 0 | 1 | 1 |
| 1996 | 1 | 1 | 2 |
| 1997 | 1 | 0 | 1 |
| 1998 | 1 | 0 | 1 |
| 2000 | 1 | 0 | 1 |
| 2001 | 1 | 0 | 1 |
| 2002 | 0 | 3 | 3 |
| 2006 | 1 | 0 | 1 |
| 2007 | 0 | 1 | 1 |
| 2008 | 0 | 1 | 1 |
| 2009 | 2 | 0 | 2 |
| 2011 | 1 | 1 | 2 |
| 2012 | 1 | 2 | 3 |
| 2013 | 1 | 3 | 4 |
| 2014 | 0 | 1 | 1 |
| 2015 | 1 | 2 | 3 |
| 2016 | 1 | 1 | 2 |
| 2017 | 0 | 2 | 2 |
| 2019 | 0 | 2 | 2 |
| 2023 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Receptor, IGF Type 1" by people in Profiles.
-
Effect of antibiotic monensin on cell proliferation and IGF1R signaling pathway in human colorectal cancer cells. Ann Med. 2023 12; 55(1):954-964.
-
Inhibition of the IGF-1-PI3K-Akt-mTORC2 pathway in lipid rafts increases neuronal vulnerability in a genetic lysosomal glycosphingolipidosis. Dis Model Mech. 2019 05 23; 12(5).
-
Oocyte-Secreted Factors Synergize With FSH to Promote Aromatase Expression in Primary Human Cumulus Cells. J Clin Endocrinol Metab. 2019 05 01; 104(5):1667-1676.
-
Klotho, an antiaging molecule, attenuates oxidant-induced alveolar epithelial cell mtDNA damage and apoptosis. Am J Physiol Lung Cell Mol Physiol. 2017 07 01; 313(1):L16-L26.
-
Genome-wide interactions between FSH and insulin-like growth factors in the regulation of human granulosa cell differentiation. Hum Reprod. 2017 04 01; 32(4):905-914.
-
A Blockade of IGF Signaling Sensitizes Human Ovarian Cancer Cells to the Anthelmintic Niclosamide-Induced Anti-Proliferative and Anticancer Activities. Cell Physiol Biochem. 2016; 39(3):871-88.
-
Small Cell Lung Cancer Screen of Oncology Drugs, Investigational Agents, and Gene and microRNA Expression. J Natl Cancer Inst. 2016 10; 108(10).
-
Antibiotic monensin synergizes with EGFR inhibitors and oxaliplatin to suppress the proliferation of human ovarian cancer cells. Sci Rep. 2015 Dec 07; 5:17523.
-
Sarcoma Cell Line Screen of Oncology Drugs and Investigational Agents Identifies Patterns Associated with Gene and microRNA Expression. Mol Cancer Ther. 2015 Nov; 14(11):2452-62.
-
Doxorubicin plus the IGF-1R antibody cixutumumab in soft tissue sarcoma: a phase I study using the TITE-CRM model. Ann Oncol. 2015 07; 26(7):1459-64.